Company news

Aligos Therapeutics, Inc. news in 2021

Aligos Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study

December 8, 2021

Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors

November 17, 2021

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results

November 3, 2021

Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021

October 27, 2021

Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study

October 10, 2021

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results

August 4, 2021

Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021

July 28, 2021

Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock

June 29, 2021

Aligos Therapeutics Announces Proposed Public Offering of Common Stock

June 27, 2021

Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital Internationa...

June 20, 2021

Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021

June 13, 2021

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial Results

May 9, 2021

Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021

May 4, 2021

Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors

April 26, 2021

Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study

April 13, 2021

Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

March 22, 2021

Aligos Therapeutics Begins Dosing with STOPS™ Molecule Drug Candidate, ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study

March 9, 2021

Decks in 2021